FDA Gives Go-ahead for Phase 1/2 Trial Testing VY-HTT01 Gene Therapy

FDA Gives Go-ahead for Phase 1/2 Trial Testing VY-HTT01 Gene Therapy

292996

FDA Gives Go-ahead for Phase 1/2 Trial Testing VY-HTT01 Gene Therapy

The U.S. Food and Drug Administration (FDA) has granted Voyager Therapeutics permission to start a clinical trial testing VY-HTT01, its investigational gene therapy for Huntington’s disease. Voyager is planning to launch the Phase 1/2 clinical trial, called VYTAL, later this year. VYTAL will be a dose-escalation study, meaning that enrolled participants will be given one of multiple increasing doses of the therapy candidate. The main goal of the trial will be to assess the safety and…

You must be logged in to read/download the full post.